VISK Viskase Holdings, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 727510 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY59.0%
TTM EPS YoY182.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-21.6%
ROA-8.2%
ROIC (approx.)-4.0%
Asset turnover—
Leverage & solvency
Liabilities / assets58.4%
Debt / equity1.52x
Current ratio1.07x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.44x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $95.28M | $90.13M | $86.54M | — | $91.16M | $97.28M | $94.19M | $0 |
| Cost of revenue | $86.78M | $79.03M | $77.54M | — | $85.30M | $85.64M | $79.78M | — |
| Gross profit | $8.50M | $11.10M | $9.00M | — | $5.87M | $11.63M | $14.41M | — |
| R&D expense | $736,000 | $649,000 | $558,000 | — | $851,000 | $668,000 | $662,000 | — |
| SG&A expense | $11.19M | $12.15M | $12.43M | — | $13.52M | $12.93M | $11.70M | — |
| Operating income | -$3.13M | -$2.02M | -$4.33M | -$1.47M | -$9.06M | -$2.63M | -$14.40M | -$325,000 |
| Pretax income | -$6.41M | -$4.83M | -$5.97M | -$1.04M | -$11.05M | -$5.91M | -$15.01M | $221,000 |
| Income tax | $28,000 | $305,000 | $748,000 | $26,000 | $1.95M | $14.35M | -$1.41M | $293,000 |
| Net income | -$6.40M | -$5.06M | -$6.69M | -$1.07M | -$12.98M | -$20.25M | -$13.59M | -$72,000 |
| EBITDA | $934,000 | $2.40M | -$105,000 | — | -$4.94M | $2.28M | -$9.02M | — |
| EPS (basic) | -0.45 | -0.35 | -0.84 | — | -2.40 | -3.74 | -2.65 | — |
| EPS (diluted) | -0.45 | -0.35 | -0.84 | — | -2.40 | -3.74 | -2.65 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Weighted avg. shares (diluted) | 14.33M | 14.33M | 7.93M | — | 5.42M | 5.42M | 5.13M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.75M | $7.91M | $28.62M | $9.22M | $7.69M | $8.91M | $5.75M | $5.70M |
| Receivables | $69.98M | $67.39M | $62.83M | $60.18M | — | — | — | — |
| Inventory | $100.34M | $105.30M | $98.85M | $96.75M | — | — | — | — |
| Current assets | $226.32M | $227.34M | $234.58M | $208.65M | $43.67M | $44.74M | $45.52M | $47.15M |
| PP&E, net | $155.59M | $147.65M | $142.95M | $141.30M | — | — | — | — |
| Goodwill | $3.04M | $3.05M | $3.07M | $3.13M | — | — | — | — |
| Intangibles | $12.20M | $12.62M | $12.89M | $13.40M | — | — | — | — |
| Total assets | $427.47M | $424.48M | $428.87M | $402.14M | $43.69M | $44.78M | $45.52M | $47.17M |
| Current liabilities | $210.73M | $123.63M | $116.94M | $214.52M | $540,000 | $803,000 | $554,000 | $1.68M |
| Short-term debt | $135.71M | $54.47M | $51.10M | $141.77M | — | — | — | — |
| Long-term debt | $135.71M | $74.93M | $79.73M | $141.77M | — | — | — | — |
| Total debt | $271.41M | $129.40M | $130.83M | $283.55M | — | — | — | — |
| Total liabilities | $249.72M | $238.87M | $237.79M | $257.78M | -$100.62M | -$115.04M | -$128.13M | -$122.82M |
| Shareholders' equity | $178.94M | $186.80M | $192.20M | $145.84M | -$923,000 | $432,000 | $1.95M | $3.01M |
| Net debt | $263.67M | $121.49M | $102.22M | $274.33M | — | — | — | — |
| Shares outstanding | 14.33M | 14.33M | 14.33M | 6.61M | 74.21M | 74.21M | 74.21M | 74.21M |
| Cash flow statement | ||||||||
| Operating cash flow | $454,000 | -$11.21M | -$16.32M | -$682,000 | $10.12M | $2.24M | $129,000 | $226,000 |
| Capital expenditure | $6.59M | $7.70M | $8.98M | — | $9.25M | $8.99M | $7.35M | — |
| Free cash flow | -$6.14M | -$18.90M | -$25.30M | — | $870,000 | -$6.75M | -$7.22M | — |
| Investing cash flow | -$6.59M | -$7.70M | -$8.98M | — | -$9.25M | -$8.99M | -$7.35M | — |
| Financing cash flow | $6.08M | -$1.75M | $44.75M | $0 | -$2.06M | $9.64M | $7.19M | $0 |
| Depreciation & amortization | $4.07M | $4.42M | $4.23M | — | $4.12M | $4.91M | $5.38M | — |
| Dividends paid | — | — | — | $0 | $0 | $0 | $1.27M | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.